Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese
  • Polish
  • Turkish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Melanoma: fecal microbiota transplant to overcome resistance to anti–PD-1?
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Melanoma: fecal microbiota transplant to overcome resistance to anti–PD-1?
Gastroenterology

Melanoma: fecal microbiota transplant to overcome resistance to anti–PD-1?

Drug
Oncology Gastroenterology

A recent study published in Science shows that modulating the gut microbiota helps advanced melanoma patients respond to anti-PD-1 immunotherapy which their tumors had previously resisted. How? Thanks to fecal microbiota transplantation (FMT).

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 18 May 2021
Updated 26 June 2024

Anti-PD-1 has been one of the major therapeutic advances of the past decade. It provides long-term clinical benefits to patients with advanced melanoma. In preclinical models and cancer patients, the efficacy of this therapy correlates with the composition of the gut microbiota. The aim of this Phase II clinical trial was to investigate whether resistance to anti–PD-1 can be overcome by modulating the gut microbiota.

Fecal microbiota and anti-PD-1: a winning combination?

The purpose of this clinical trial was to evaluate the safety and efficacy of FMT in combination with an anti-PD-1 agent (pembrolizumab) in metastatic melanoma patients previously refractory to this therapy. Fifteen patients received an anti-PD-1 (administered every 3 weeks until change) and a single FMT from seven donors who had previously shown a complete (4 patients) or partial (3 patients) response to immunotherapy. Radiographic assessments were performed every 12 weeks.

The gut microbiota of recipients and donors was analyzed via shotgun sequencing. For each recipient, one pre-FMT sample (collected 7 to 21 days beforehand) and all post-FMT samples (collected weekly for 12 weeks, then every 3 weeks) were sequenced. Patients’ progress was followed for 12 months on average.

FMT alters the gut microbiota

This combination was very well tolerated and provided significant clinical benefit in 6 patients, with regression or stabilization of the tumor for more than a year. In these patients, the median survival was 14 months.

The composition of the gut microbiota of the 15 FMT patients changed following FMT, regardless of whether the patient responded to immunotherapy. The gut microbiota composition of the 6 responders became more similar to that of the donors than did that of the non-responders. Their gut microbiota became richer in species of Firmicutes (Lachnospiraceae and Ruminococcaceae) and Actinobacteria (Bifidobacteriaceae and Coriobacteriaceae) and depleted in Bacteroidetes species.

FMT and immunotherapy reshape immune response

In the 6 responders, immunological changes in the blood and at tumor sites suggest increased activation of immune cells (increased CD8+ T cell activation, decreased frequency of IL-8). In addition, the responders had distinct proteomic and metabolomic signatures, with these changes apparently regulated by the gut microbiota. On the other hand, according to the researchers, non-responders may be refractory to immunotherapy for multiple reasons linked to the composition of their gut microbiota.

Although these findings require further investigation with broader clinical trials, the study suggests that a single FMT administered with a PD-1 inhibitor is enough to successfully change responders’ gut microbiota and reprogram the tumor microenvironment to overcome immunotherapy resistance. FMT changes the composition of the microbiota, improving the efficacy of anti-PD-1 therapy and inducing clinical responses in patients with immunotherapy-refractory melanoma.

 

Sources

D Davar, Dzutsev AK, McCulloch JA et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 2021 Feb 5;371(6529):595-602.

Tags
Immunity Cancer Immunotherapy Melanoma Microbiome Flora
    Created 18 May 2021
    Updated 26 June 2024

    About this article

    To know more about this topic.

    Main topic

    Drug

    Medical practice

    Oncology Gastroenterology

    Content type

    News
    Gastroenterology

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irrita...

    Find out more

    Probiotics: what exactly are we talking about?

    From the Latin pro and Greek bios meaning “for life”, the term “probiotic” was suggested over 60 year...

    Find out more

    How do you choose a probiotic for your patient?

    Faced with a plethora of products on the market, it's not always easy for health professionals to sug...

    Find out more

    The Janus face of Antibiotics: Life Savers and Microbiota Disruptors

    A page turns: with the advent of antibiotics in the...

    Find out more

    Fecal transplantation - ready for prime time?

    Congress review By Pr. Danny De Looze Department of Gastroenterology University Hospital Gent, Belgi...

    Find out more

    Focus on antibiotic associated diarrhea (AAD)

    Find out more

    Dampening gastrointestinal inflammation through nutrition

    by Dr Genelle Healey

    Find out more

    Continue reading

    News
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article
    20.03.2025

    Entacapone and the gut: a hidden impact on parkinson’s care

    Read the article
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Russian
    • Portuguese
    • Polish
    • Turkish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo